Ellen Burnham
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alcoholism | 37 | 2023 | 713 | 7.250 |
Why?
| Bronchoalveolar Lavage Fluid | 22 | 2022 | 608 | 2.170 |
Why?
| Lung | 18 | 2022 | 3672 | 1.960 |
Why?
| Alcohol-Related Disorders | 7 | 2015 | 110 | 1.830 |
Why?
| Respiratory Insufficiency | 6 | 2022 | 292 | 1.510 |
Why?
| Pneumonia | 9 | 2023 | 576 | 1.480 |
Why?
| Ethanol | 11 | 2022 | 549 | 1.440 |
Why?
| Respiratory Mucosa | 4 | 2020 | 258 | 1.400 |
Why?
| Acute Lung Injury | 10 | 2022 | 300 | 1.370 |
Why?
| Critical Illness | 20 | 2023 | 645 | 1.360 |
Why?
| Cannabis | 4 | 2022 | 381 | 1.360 |
Why?
| Critical Care | 9 | 2021 | 477 | 1.130 |
Why?
| Gene Expression | 3 | 2020 | 1436 | 1.110 |
Why?
| Macrophages, Alveolar | 9 | 2021 | 357 | 1.100 |
Why?
| Sepsis | 5 | 2020 | 515 | 1.090 |
Why?
| Intensive Care Units | 17 | 2022 | 622 | 1.050 |
Why?
| Cytokines | 8 | 2023 | 1853 | 1.040 |
Why?
| Marijuana Smoking | 2 | 2021 | 224 | 1.010 |
Why?
| Middle Aged | 63 | 2022 | 26998 | 0.970 |
Why?
| Inflammation Mediators | 4 | 2016 | 479 | 0.960 |
Why?
| Central Nervous System Depressants | 2 | 2021 | 82 | 0.910 |
Why?
| Streptococcus pneumoniae | 2 | 2018 | 133 | 0.910 |
Why?
| Pulmonary Alveoli | 6 | 2016 | 376 | 0.900 |
Why?
| Pulmonary Fibrosis | 3 | 2022 | 330 | 0.890 |
Why?
| Acetates | 2 | 2021 | 96 | 0.880 |
Why?
| Stem Cells | 5 | 2015 | 546 | 0.880 |
Why?
| Mentors | 4 | 2014 | 162 | 0.860 |
Why?
| Adult | 57 | 2022 | 30719 | 0.850 |
Why?
| Smoking | 8 | 2021 | 1457 | 0.840 |
Why?
| Substance Withdrawal Syndrome | 4 | 2021 | 160 | 0.830 |
Why?
| Leukocytes, Mononuclear | 3 | 2017 | 501 | 0.830 |
Why?
| Humans | 118 | 2023 | 115589 | 0.830 |
Why?
| Lung Diseases | 3 | 2021 | 710 | 0.820 |
Why?
| Hospital Mortality | 6 | 2020 | 779 | 0.820 |
Why?
| Cerebrovascular Circulation | 2 | 2021 | 202 | 0.810 |
Why?
| Hospitalization | 9 | 2023 | 1765 | 0.800 |
Why?
| Burnout, Professional | 4 | 2022 | 322 | 0.760 |
Why?
| Thalamus | 2 | 2021 | 78 | 0.750 |
Why?
| Male | 71 | 2022 | 55949 | 0.750 |
Why?
| Female | 73 | 2022 | 59913 | 0.750 |
Why?
| Case-Control Studies | 14 | 2022 | 3022 | 0.750 |
Why?
| Behavior | 1 | 2021 | 91 | 0.730 |
Why?
| Noninvasive Ventilation | 1 | 2020 | 32 | 0.700 |
Why?
| Hallucinogens | 1 | 2021 | 73 | 0.700 |
Why?
| Cigarette Smoking | 2 | 2020 | 80 | 0.660 |
Why?
| RNA, Messenger | 5 | 2020 | 2574 | 0.660 |
Why?
| Opioid-Related Disorders | 2 | 2023 | 422 | 0.650 |
Why?
| Glutathione | 5 | 2016 | 303 | 0.640 |
Why?
| Survivors | 6 | 2013 | 404 | 0.640 |
Why?
| Intubation, Intratracheal | 1 | 2020 | 215 | 0.630 |
Why?
| Respiration, Artificial | 10 | 2020 | 526 | 0.630 |
Why?
| Epithelial Cells | 4 | 2021 | 961 | 0.630 |
Why?
| Antioxidants | 4 | 2016 | 533 | 0.620 |
Why?
| Pneumonia, Pneumococcal | 1 | 2018 | 37 | 0.620 |
Why?
| Physicians, Women | 1 | 2019 | 55 | 0.620 |
Why?
| Toll-Like Receptor 2 | 2 | 2016 | 112 | 0.610 |
Why?
| Tobacco Products | 1 | 2019 | 99 | 0.600 |
Why?
| Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.590 |
Why?
| Bronchoalveolar Lavage | 7 | 2023 | 89 | 0.580 |
Why?
| Biomedical Research | 2 | 2021 | 588 | 0.580 |
Why?
| Organ Dysfunction Scores | 1 | 2016 | 39 | 0.540 |
Why?
| Blood-Air Barrier | 2 | 2008 | 10 | 0.540 |
Why?
| Marijuana Abuse | 1 | 2018 | 209 | 0.540 |
Why?
| Toll-Like Receptor 4 | 2 | 2016 | 285 | 0.530 |
Why?
| Inflammation | 7 | 2021 | 2499 | 0.500 |
Why?
| Azithromycin | 1 | 2015 | 80 | 0.500 |
Why?
| Glycerophospholipids | 3 | 2021 | 29 | 0.490 |
Why?
| Tomography, X-Ray Computed | 2 | 2014 | 2392 | 0.470 |
Why?
| Professional Autonomy | 1 | 2013 | 25 | 0.460 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1098 | 0.450 |
Why?
| Radiography, Thoracic | 1 | 2014 | 165 | 0.450 |
Why?
| Research Support as Topic | 2 | 2011 | 108 | 0.440 |
Why?
| Oxidative Stress | 5 | 2017 | 1093 | 0.440 |
Why?
| Lipopolysaccharides | 5 | 2017 | 826 | 0.440 |
Why?
| Cells, Cultured | 8 | 2018 | 3914 | 0.440 |
Why?
| Immunity, Innate | 1 | 2018 | 731 | 0.430 |
Why?
| Intensive Care Units, Pediatric | 1 | 2013 | 147 | 0.410 |
Why?
| Retrospective Studies | 20 | 2023 | 12608 | 0.410 |
Why?
| Bronchoscopy | 3 | 2023 | 245 | 0.410 |
Why?
| Drugs, Chinese Herbal | 1 | 2012 | 13 | 0.400 |
Why?
| Academic Medical Centers | 2 | 2014 | 414 | 0.400 |
Why?
| Venous Thromboembolism | 3 | 2020 | 234 | 0.390 |
Why?
| Asthma | 2 | 2022 | 2066 | 0.380 |
Why?
| Burns | 3 | 2022 | 242 | 0.370 |
Why?
| Biomarkers | 13 | 2022 | 3467 | 0.370 |
Why?
| Gene Expression Regulation | 6 | 2022 | 2353 | 0.370 |
Why?
| Aged | 25 | 2022 | 19250 | 0.360 |
Why?
| Anti-Bacterial Agents | 2 | 2019 | 1483 | 0.360 |
Why?
| Personnel Selection | 1 | 2011 | 67 | 0.350 |
Why?
| Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.340 |
Why?
| Cohort Studies | 13 | 2020 | 4944 | 0.340 |
Why?
| Malondialdehyde | 2 | 2021 | 26 | 0.340 |
Why?
| Personnel Staffing and Scheduling | 1 | 2010 | 79 | 0.340 |
Why?
| Acetaldehyde | 2 | 2021 | 20 | 0.340 |
Why?
| Muscular Diseases | 3 | 2017 | 104 | 0.340 |
Why?
| Medical Staff, Hospital | 1 | 2010 | 74 | 0.340 |
Why?
| Pneumococcal Infections | 1 | 2010 | 91 | 0.340 |
Why?
| Hypnotics and Sedatives | 2 | 2008 | 134 | 0.330 |
Why?
| Smokers | 2 | 2021 | 147 | 0.320 |
Why?
| Multiple Organ Failure | 3 | 2006 | 144 | 0.320 |
Why?
| Anesthesiology | 1 | 2008 | 36 | 0.310 |
Why?
| Pulmonary Embolism | 3 | 2019 | 182 | 0.310 |
Why?
| Epidemics | 2 | 2019 | 70 | 0.310 |
Why?
| Sexism | 2 | 2019 | 43 | 0.300 |
Why?
| Burns, Inhalation | 2 | 2017 | 9 | 0.300 |
Why?
| Airway Extubation | 3 | 2013 | 45 | 0.300 |
Why?
| Endothelial Cells | 4 | 2011 | 695 | 0.290 |
Why?
| Betacoronavirus | 2 | 2020 | 254 | 0.290 |
Why?
| Toll-Like Receptors | 2 | 2018 | 166 | 0.290 |
Why?
| Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.280 |
Why?
| Marijuana Use | 2 | 2022 | 164 | 0.280 |
Why?
| Young Adult | 12 | 2019 | 10470 | 0.280 |
Why?
| Deglutition Disorders | 3 | 2013 | 119 | 0.280 |
Why?
| Risk Factors | 16 | 2020 | 8697 | 0.280 |
Why?
| Multivariate Analysis | 5 | 2023 | 1440 | 0.280 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 990 | 0.270 |
Why?
| Fibronectins | 1 | 2007 | 108 | 0.270 |
Why?
| Tissue Plasminogen Activator | 2 | 2018 | 228 | 0.270 |
Why?
| APACHE | 4 | 2013 | 59 | 0.270 |
Why?
| Preoperative Care | 1 | 2008 | 318 | 0.270 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 145 | 0.260 |
Why?
| Pediatrics | 1 | 2013 | 986 | 0.260 |
Why?
| Immunity, Cellular | 2 | 2018 | 262 | 0.260 |
Why?
| Quality of Life | 2 | 2013 | 2385 | 0.250 |
Why?
| Nutritional Physiological Phenomena | 1 | 2005 | 48 | 0.250 |
Why?
| Pneumonia, Viral | 2 | 2020 | 344 | 0.250 |
Why?
| Coronavirus Infections | 2 | 2020 | 336 | 0.250 |
Why?
| Patient Acceptance of Health Care | 3 | 2019 | 682 | 0.250 |
Why?
| Alcohol Drinking | 4 | 2021 | 650 | 0.240 |
Why?
| Bacterial Proteins | 1 | 2010 | 739 | 0.240 |
Why?
| Aged, 80 and over | 10 | 2022 | 6417 | 0.240 |
Why?
| Anticoagulants | 2 | 2019 | 549 | 0.240 |
Why?
| Internship and Residency | 1 | 2013 | 951 | 0.230 |
Why?
| E-Selectin | 1 | 2004 | 54 | 0.230 |
Why?
| Shock, Septic | 2 | 2022 | 185 | 0.220 |
Why?
| Lung Injury | 2 | 2016 | 199 | 0.220 |
Why?
| Interferons | 2 | 2016 | 152 | 0.220 |
Why?
| Interleukin-1beta | 2 | 2017 | 370 | 0.220 |
Why?
| Pilot Projects | 4 | 2021 | 1377 | 0.220 |
Why?
| Dyspnea | 2 | 2019 | 223 | 0.210 |
Why?
| Polyneuropathies | 2 | 2017 | 50 | 0.210 |
Why?
| Fibroblasts | 3 | 2013 | 839 | 0.210 |
Why?
| Age Factors | 4 | 2021 | 2907 | 0.200 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 23 | 0.200 |
Why?
| Double-Blind Method | 4 | 2014 | 1659 | 0.200 |
Why?
| Epithelium | 2 | 2021 | 297 | 0.200 |
Why?
| Smoke Inhalation Injury | 2 | 2012 | 19 | 0.200 |
Why?
| Delirium | 1 | 2023 | 66 | 0.200 |
Why?
| Administration, Inhalation | 2 | 2021 | 644 | 0.200 |
Why?
| Patient Discharge | 2 | 2018 | 770 | 0.200 |
Why?
| United States | 12 | 2022 | 12295 | 0.200 |
Why?
| Interleukin-8 | 3 | 2018 | 241 | 0.190 |
Why?
| Alcohol Abstinence | 1 | 2021 | 10 | 0.190 |
Why?
| Neutrophils | 3 | 2017 | 1172 | 0.190 |
Why?
| Cell Count | 2 | 2015 | 305 | 0.190 |
Why?
| Critical Care Outcomes | 1 | 2020 | 12 | 0.190 |
Why?
| Status Asthmaticus | 1 | 2020 | 11 | 0.190 |
Why?
| Physicians | 3 | 2022 | 776 | 0.190 |
Why?
| Dysbiosis | 1 | 2022 | 146 | 0.190 |
Why?
| Pandemics | 4 | 2022 | 1334 | 0.180 |
Why?
| Comorbidity | 4 | 2020 | 1473 | 0.180 |
Why?
| Phagocytosis | 2 | 2014 | 355 | 0.180 |
Why?
| Random Allocation | 1 | 2021 | 337 | 0.180 |
Why?
| Immunoglobulin A | 1 | 2021 | 173 | 0.180 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 317 | 0.170 |
Why?
| Capacity Building | 1 | 2020 | 51 | 0.170 |
Why?
| Career Choice | 2 | 2012 | 183 | 0.170 |
Why?
| Permeability | 2 | 2012 | 150 | 0.170 |
Why?
| von Willebrand Factor | 1 | 2019 | 56 | 0.170 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 243 | 0.170 |
Why?
| Homeostasis | 1 | 2003 | 577 | 0.170 |
Why?
| Faculty, Medical | 1 | 2022 | 234 | 0.170 |
Why?
| Needs Assessment | 1 | 2021 | 318 | 0.170 |
Why?
| Length of Stay | 4 | 2020 | 958 | 0.170 |
Why?
| Cardiology | 1 | 2022 | 260 | 0.170 |
Why?
| Chemokines | 2 | 2018 | 214 | 0.170 |
Why?
| Wounds and Injuries | 1 | 2006 | 725 | 0.170 |
Why?
| Disaster Planning | 1 | 2020 | 77 | 0.170 |
Why?
| Brain | 3 | 2021 | 2373 | 0.170 |
Why?
| Animals | 16 | 2022 | 32102 | 0.160 |
Why?
| Speech Therapy | 1 | 2019 | 21 | 0.160 |
Why?
| Endothelium, Vascular | 1 | 2005 | 845 | 0.160 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2018 | 29 | 0.160 |
Why?
| Macrolides | 1 | 2019 | 56 | 0.160 |
Why?
| Community-Acquired Infections | 1 | 2020 | 140 | 0.160 |
Why?
| Statistics, Nonparametric | 4 | 2014 | 390 | 0.160 |
Why?
| Vecuronium Bromide | 1 | 2018 | 6 | 0.160 |
Why?
| Atracurium | 1 | 2018 | 13 | 0.150 |
Why?
| Heart Failure, Systolic | 1 | 2018 | 20 | 0.150 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 20 | 0.150 |
Why?
| Pulmonary Ventilation | 1 | 2018 | 68 | 0.150 |
Why?
| Neuromuscular Blocking Agents | 1 | 2018 | 23 | 0.150 |
Why?
| Occupational Therapy | 1 | 2019 | 73 | 0.150 |
Why?
| Cardiologists | 1 | 2018 | 41 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2018 | 1137 | 0.150 |
Why?
| Apoptosis | 3 | 2014 | 2377 | 0.150 |
Why?
| Factor Xa Inhibitors | 1 | 2018 | 138 | 0.150 |
Why?
| Societies, Medical | 1 | 2021 | 684 | 0.150 |
Why?
| Treatment Outcome | 9 | 2022 | 9159 | 0.150 |
Why?
| Chemokine CCL2 | 1 | 2017 | 105 | 0.150 |
Why?
| Heparin | 1 | 2019 | 227 | 0.150 |
Why?
| Hospitals, University | 2 | 2015 | 172 | 0.150 |
Why?
| Hospitalists | 1 | 2020 | 173 | 0.140 |
Why?
| Transforming Growth Factor beta | 3 | 2022 | 446 | 0.140 |
Why?
| Tobacco Use | 1 | 2017 | 59 | 0.140 |
Why?
| Interleukin-6 | 2 | 2018 | 677 | 0.140 |
Why?
| Cystine | 1 | 2016 | 14 | 0.140 |
Why?
| Cyclooxygenase 2 | 1 | 2017 | 164 | 0.140 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 930 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2014 | 4440 | 0.140 |
Why?
| Interleukin-10 | 1 | 2018 | 299 | 0.140 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2016 | 503 | 0.140 |
Why?
| Disulfides | 1 | 2016 | 91 | 0.130 |
Why?
| Prevalence | 2 | 2015 | 2264 | 0.130 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 511 | 0.130 |
Why?
| Physical Therapy Modalities | 1 | 2019 | 269 | 0.130 |
Why?
| Teichoic Acids | 1 | 2016 | 12 | 0.130 |
Why?
| Fibrinolytic Agents | 1 | 2018 | 233 | 0.130 |
Why?
| DNA, Bacterial | 1 | 2017 | 309 | 0.130 |
Why?
| Respiratory Tract Diseases | 1 | 2017 | 142 | 0.130 |
Why?
| RNA Splicing | 1 | 2017 | 244 | 0.130 |
Why?
| Alternative Splicing | 1 | 2017 | 187 | 0.130 |
Why?
| Cannabinoids | 1 | 2017 | 116 | 0.130 |
Why?
| Proteins | 2 | 2021 | 920 | 0.130 |
Why?
| Hospitals | 1 | 2020 | 585 | 0.130 |
Why?
| Patient Selection | 2 | 2023 | 654 | 0.130 |
Why?
| Inflammasomes | 1 | 2017 | 116 | 0.130 |
Why?
| Signal Transduction | 3 | 2022 | 4541 | 0.130 |
Why?
| Cysteine | 1 | 2016 | 173 | 0.130 |
Why?
| Urinary Bladder | 1 | 2017 | 165 | 0.130 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 97 | 0.130 |
Why?
| Cholesterol | 1 | 2017 | 369 | 0.120 |
Why?
| Interprofessional Relations | 1 | 2017 | 258 | 0.120 |
Why?
| Oxidation-Reduction | 2 | 2016 | 924 | 0.120 |
Why?
| Acetylcysteine | 1 | 2016 | 144 | 0.120 |
Why?
| Transcriptome | 1 | 2020 | 736 | 0.120 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 140 | 0.120 |
Why?
| Severity of Illness Index | 5 | 2016 | 2578 | 0.120 |
Why?
| Third-Party Consent | 1 | 2013 | 8 | 0.120 |
Why?
| Quality Improvement | 1 | 2021 | 958 | 0.110 |
Why?
| Combined Modality Therapy | 1 | 2017 | 1127 | 0.110 |
Why?
| Reproducibility of Results | 3 | 2019 | 2800 | 0.110 |
Why?
| Disease Progression | 1 | 2020 | 2418 | 0.110 |
Why?
| Competency-Based Education | 1 | 2014 | 66 | 0.110 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 72 | 0.110 |
Why?
| Aging | 2 | 2017 | 1631 | 0.110 |
Why?
| Professional Competence | 1 | 2014 | 86 | 0.110 |
Why?
| T-Lymphocyte Subsets | 1 | 2015 | 383 | 0.110 |
Why?
| Chemokine CCL5 | 1 | 2013 | 46 | 0.110 |
Why?
| Atherosclerosis | 1 | 2017 | 341 | 0.110 |
Why?
| Total Lung Capacity | 1 | 2013 | 30 | 0.110 |
Why?
| Growth Differentiation Factor 15 | 1 | 2013 | 34 | 0.110 |
Why?
| Transcription, Genetic | 2 | 2010 | 1310 | 0.110 |
Why?
| Pulmonary Diffusing Capacity | 1 | 2013 | 64 | 0.110 |
Why?
| Logistic Models | 5 | 2017 | 1856 | 0.110 |
Why?
| Magnetic Resonance Imaging | 2 | 2021 | 3071 | 0.110 |
Why?
| Financial Support | 1 | 2012 | 21 | 0.110 |
Why?
| Speech-Language Pathology | 1 | 2012 | 17 | 0.100 |
Why?
| Informed Consent | 1 | 2013 | 161 | 0.100 |
Why?
| Interleukin-12 | 1 | 2013 | 110 | 0.100 |
Why?
| Cell Survival | 1 | 2015 | 1024 | 0.100 |
Why?
| Lymphatic Vessels | 1 | 2012 | 54 | 0.100 |
Why?
| Prospective Studies | 6 | 2021 | 6264 | 0.100 |
Why?
| Vital Capacity | 1 | 2013 | 277 | 0.100 |
Why?
| Serotonin | 1 | 2014 | 296 | 0.100 |
Why?
| Neuregulin-1 | 1 | 2012 | 41 | 0.100 |
Why?
| Pepsin A | 1 | 2011 | 18 | 0.100 |
Why?
| Chemokine CXCL12 | 1 | 2012 | 74 | 0.100 |
Why?
| Ubiquitin | 1 | 2012 | 64 | 0.100 |
Why?
| Lipid Peroxidation | 1 | 2012 | 138 | 0.100 |
Why?
| Phytotherapy | 1 | 2012 | 66 | 0.100 |
Why?
| Capillaries | 2 | 2009 | 92 | 0.100 |
Why?
| Respiratory Aspiration | 1 | 2011 | 31 | 0.100 |
Why?
| Respiratory Function Tests | 1 | 2013 | 535 | 0.100 |
Why?
| MicroRNAs | 1 | 2017 | 607 | 0.100 |
Why?
| Genetic Testing | 1 | 2013 | 382 | 0.090 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 795 | 0.090 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2011 | 57 | 0.090 |
Why?
| Night Care | 1 | 2010 | 4 | 0.090 |
Why?
| Cell Differentiation | 2 | 2015 | 1700 | 0.090 |
Why?
| ROC Curve | 2 | 2017 | 451 | 0.090 |
Why?
| Collagen | 1 | 2012 | 415 | 0.090 |
Why?
| After-Hours Care | 1 | 2010 | 15 | 0.090 |
Why?
| Awards and Prizes | 1 | 2011 | 56 | 0.090 |
Why?
| Nervous System Diseases | 1 | 2013 | 253 | 0.090 |
Why?
| Mice | 7 | 2022 | 15052 | 0.090 |
Why?
| Microbiota | 1 | 2017 | 652 | 0.090 |
Why?
| Organizational Culture | 1 | 2011 | 121 | 0.090 |
Why?
| Autoantibodies | 1 | 2017 | 1360 | 0.090 |
Why?
| Mice, Inbred C57BL | 5 | 2021 | 4773 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 1405 | 0.090 |
Why?
| Colony-Forming Units Assay | 1 | 2009 | 90 | 0.090 |
Why?
| Peer Group | 1 | 2011 | 206 | 0.090 |
Why?
| Focus Groups | 1 | 2011 | 393 | 0.080 |
Why?
| Lung Transplantation | 1 | 2011 | 246 | 0.080 |
Why?
| Bayes Theorem | 2 | 2022 | 334 | 0.080 |
Why?
| Program Development | 1 | 2011 | 350 | 0.080 |
Why?
| Gastroesophageal Reflux | 1 | 2011 | 235 | 0.080 |
Why?
| Thyrotoxicosis | 1 | 2008 | 8 | 0.080 |
Why?
| Hypertension, Pulmonary | 2 | 2011 | 1749 | 0.080 |
Why?
| Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.080 |
Why?
| Computers | 1 | 2008 | 60 | 0.080 |
Why?
| Chest Pain | 1 | 2008 | 82 | 0.080 |
Why?
| Radionuclide Imaging | 1 | 2008 | 121 | 0.080 |
Why?
| Burn Units | 2 | 2022 | 26 | 0.080 |
Why?
| Half-Life | 1 | 2008 | 145 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 3 | 2019 | 1870 | 0.080 |
Why?
| Quality Assurance, Health Care | 1 | 2010 | 315 | 0.070 |
Why?
| Schools | 1 | 2011 | 400 | 0.070 |
Why?
| Sex Factors | 1 | 2013 | 1736 | 0.070 |
Why?
| Staphylococcus aureus | 1 | 2011 | 385 | 0.070 |
Why?
| Myeloid Cells | 1 | 2008 | 127 | 0.070 |
Why?
| Patient Readmission | 3 | 2019 | 609 | 0.070 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 23 | 0.070 |
Why?
| Cross-Sectional Studies | 4 | 2022 | 4435 | 0.070 |
Why?
| Cocaine-Related Disorders | 1 | 2008 | 107 | 0.070 |
Why?
| Lung Diseases, Interstitial | 1 | 2012 | 520 | 0.070 |
Why?
| Radiopharmaceuticals | 1 | 2008 | 187 | 0.070 |
Why?
| Georgia | 2 | 2004 | 62 | 0.070 |
Why?
| Cell Separation | 3 | 2016 | 293 | 0.070 |
Why?
| Indicators and Reagents | 1 | 2007 | 100 | 0.070 |
Why?
| Respiration Disorders | 1 | 2007 | 68 | 0.070 |
Why?
| Nursing Staff, Hospital | 1 | 2009 | 124 | 0.070 |
Why?
| Pulmonary Artery | 2 | 2013 | 1031 | 0.070 |
Why?
| Body Fluids | 1 | 2007 | 58 | 0.070 |
Why?
| Stem Cell Transplantation | 1 | 2008 | 151 | 0.070 |
Why?
| Thrombocytopenia | 2 | 2019 | 175 | 0.070 |
Why?
| NIH 3T3 Cells | 1 | 2007 | 137 | 0.070 |
Why?
| Program Evaluation | 1 | 2011 | 836 | 0.070 |
Why?
| Propensity Score | 2 | 2017 | 225 | 0.070 |
Why?
| Matrix Metalloproteinases | 1 | 2007 | 87 | 0.070 |
Why?
| Flow Cytometry | 1 | 2009 | 1083 | 0.070 |
Why?
| Pneumonia, Bacterial | 1 | 2006 | 107 | 0.060 |
Why?
| Adolescent | 6 | 2022 | 17890 | 0.060 |
Why?
| T-Lymphocytes | 1 | 2013 | 1756 | 0.060 |
Why?
| Research Design | 1 | 2011 | 946 | 0.060 |
Why?
| Neoplasms | 1 | 2018 | 2118 | 0.060 |
Why?
| Hemorrhage | 2 | 2019 | 618 | 0.060 |
Why?
| Colorado | 4 | 2022 | 4113 | 0.060 |
Why?
| Databases, Factual | 2 | 2019 | 1138 | 0.060 |
Why?
| Surveys and Questionnaires | 2 | 2022 | 4665 | 0.060 |
Why?
| Observation | 1 | 2004 | 50 | 0.060 |
Why?
| Dimercaprol | 1 | 2023 | 6 | 0.060 |
Why?
| Time Factors | 4 | 2018 | 6165 | 0.060 |
Why?
| Hydroxyethyl Starch Derivatives | 1 | 2003 | 7 | 0.050 |
Why?
| Nutritional Status | 1 | 2005 | 289 | 0.050 |
Why?
| Body Surface Area | 1 | 2022 | 27 | 0.050 |
Why?
| rhoA GTP-Binding Protein | 2 | 2014 | 75 | 0.050 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2022 | 54 | 0.050 |
Why?
| North America | 1 | 2022 | 261 | 0.050 |
Why?
| Vasopressins | 1 | 2022 | 57 | 0.050 |
Why?
| Mice, Knockout | 2 | 2021 | 2604 | 0.050 |
Why?
| rho-Associated Kinases | 2 | 2014 | 81 | 0.050 |
Why?
| Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.050 |
Why?
| Transcytosis | 1 | 2021 | 9 | 0.050 |
Why?
| Vasoconstrictor Agents | 1 | 2022 | 113 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2021 | 3580 | 0.050 |
Why?
| Naltrexone | 1 | 2022 | 83 | 0.050 |
Why?
| Blood Alcohol Content | 1 | 2021 | 5 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 207 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 172 | 0.050 |
Why?
| Cilia | 1 | 2022 | 162 | 0.050 |
Why?
| Bleomycin | 1 | 2022 | 232 | 0.050 |
Why?
| Ligands | 1 | 2023 | 569 | 0.050 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2009 | 758 | 0.050 |
Why?
| Containment of Biohazards | 1 | 2020 | 11 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2015 | 1243 | 0.050 |
Why?
| Prognosis | 3 | 2013 | 3339 | 0.040 |
Why?
| Medical Oncology | 1 | 2022 | 230 | 0.040 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 56 | 0.040 |
Why?
| Incidence | 2 | 2003 | 2335 | 0.040 |
Why?
| Protein Transport | 1 | 2021 | 400 | 0.040 |
Why?
| Chronic Disease | 3 | 2015 | 1598 | 0.040 |
Why?
| Pharmacoepidemiology | 1 | 2019 | 20 | 0.040 |
Why?
| Fellowships and Scholarships | 1 | 2022 | 241 | 0.040 |
Why?
| Leadership | 1 | 2022 | 302 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 126 | 0.040 |
Why?
| Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
| Coronary Circulation | 1 | 2018 | 128 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2022 | 551 | 0.040 |
Why?
| Illinois | 1 | 2017 | 37 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 130 | 0.040 |
Why?
| Hospital Charges | 1 | 2017 | 39 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| Postoperative Complications | 1 | 2008 | 2161 | 0.040 |
Why?
| Hospitals, Urban | 1 | 2018 | 129 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| Administration, Oral | 1 | 2019 | 734 | 0.040 |
Why?
| Dried Blood Spot Testing | 1 | 2017 | 71 | 0.040 |
Why?
| Venous Thrombosis | 1 | 2019 | 145 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2018 | 621 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 302 | 0.030 |
Why?
| Sex Distribution | 1 | 2017 | 337 | 0.030 |
Why?
| RNA Precursors | 1 | 2017 | 136 | 0.030 |
Why?
| Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 31 | 0.030 |
Why?
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| Capillary Leak Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| Cell Communication | 1 | 2017 | 282 | 0.030 |
Why?
| Cognition | 1 | 2023 | 980 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 347 | 0.030 |
Why?
| Cause of Death | 1 | 2017 | 368 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2017 | 225 | 0.030 |
Why?
| Capillary Permeability | 1 | 2016 | 138 | 0.030 |
Why?
| Risk | 1 | 2018 | 819 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2022 | 844 | 0.030 |
Why?
| Ventricular Function, Left | 1 | 2018 | 467 | 0.030 |
Why?
| Interferon-alpha | 1 | 2016 | 186 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2017 | 489 | 0.030 |
Why?
| Linear Models | 1 | 2017 | 776 | 0.030 |
Why?
| Coculture Techniques | 1 | 2015 | 202 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1805 | 0.030 |
Why?
| Interleukin-4 | 1 | 2015 | 209 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2017 | 732 | 0.030 |
Why?
| Gastrointestinal Tract | 1 | 2016 | 168 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 815 | 0.030 |
Why?
| Phylogeny | 1 | 2017 | 805 | 0.030 |
Why?
| Mental Competency | 1 | 2013 | 25 | 0.030 |
Why?
| Nanoparticles | 1 | 2017 | 316 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 962 | 0.030 |
Why?
| Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| Confidence Intervals | 1 | 2014 | 309 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 1219 | 0.030 |
Why?
| Ventilator Weaning | 1 | 2013 | 34 | 0.030 |
Why?
| Vascular Endothelial Growth Factor D | 1 | 2012 | 12 | 0.030 |
Why?
| Tidal Volume | 1 | 2013 | 74 | 0.030 |
Why?
| Biological Transport | 1 | 2014 | 375 | 0.030 |
Why?
| Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.030 |
Why?
| Lymphangiogenesis | 1 | 2012 | 24 | 0.030 |
Why?
| Thymus Gland | 1 | 2014 | 299 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 2013 | 249 | 0.030 |
Why?
| Fibrosis | 1 | 2015 | 457 | 0.030 |
Why?
| Healthcare Disparities | 1 | 2018 | 485 | 0.030 |
Why?
| National Institutes of Health (U.S.) | 1 | 2012 | 107 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2015 | 449 | 0.030 |
Why?
| Fluid Therapy | 1 | 2013 | 122 | 0.030 |
Why?
| Protein Binding | 1 | 2017 | 1917 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2015 | 645 | 0.020 |
Why?
| Observer Variation | 1 | 2012 | 297 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2017 | 2262 | 0.020 |
Why?
| Proteomics | 1 | 2017 | 859 | 0.020 |
Why?
| Extracellular Matrix | 1 | 2015 | 439 | 0.020 |
Why?
| Bronchiolitis Obliterans | 1 | 2011 | 66 | 0.020 |
Why?
| Research Personnel | 1 | 2012 | 153 | 0.020 |
Why?
| Microbial Viability | 1 | 2011 | 79 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2012 | 374 | 0.020 |
Why?
| World Health Organization | 1 | 2011 | 106 | 0.020 |
Why?
| Blood Pressure | 1 | 2017 | 1537 | 0.020 |
Why?
| Autoimmune Diseases | 1 | 2014 | 395 | 0.020 |
Why?
| Superoxides | 1 | 2011 | 215 | 0.020 |
Why?
| Immunomodulation | 1 | 2011 | 85 | 0.020 |
Why?
| Metabolomics | 1 | 2015 | 538 | 0.020 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 263 | 0.020 |
Why?
| Viruses | 1 | 2011 | 94 | 0.020 |
Why?
| Injury Severity Score | 1 | 2012 | 458 | 0.020 |
Why?
| Radiography | 1 | 2012 | 826 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 2012 | 302 | 0.020 |
Why?
| Species Specificity | 1 | 2011 | 552 | 0.020 |
Why?
| rho GTP-Binding Proteins | 1 | 2010 | 62 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1536 | 0.020 |
Why?
| Mitochondria | 1 | 2015 | 750 | 0.020 |
Why?
| Amides | 1 | 2010 | 88 | 0.020 |
Why?
| Cell Death | 1 | 2011 | 326 | 0.020 |
Why?
| Phosphorylation | 1 | 2014 | 1571 | 0.020 |
Why?
| Endoscopy, Gastrointestinal | 1 | 2011 | 202 | 0.020 |
Why?
| Lung Compliance | 1 | 2009 | 49 | 0.020 |
Why?
| Physician-Nurse Relations | 1 | 2009 | 15 | 0.020 |
Why?
| Biopsy | 1 | 2012 | 1056 | 0.020 |
Why?
| Leisure Activities | 1 | 2009 | 24 | 0.020 |
Why?
| AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| Cell Fusion | 1 | 2008 | 50 | 0.020 |
Why?
| Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| Triiodothyronine | 1 | 2008 | 43 | 0.020 |
Why?
| Rats | 1 | 2017 | 5034 | 0.020 |
Why?
| Leukocyte Common Antigens | 1 | 2008 | 76 | 0.020 |
Why?
| Nurse Administrators | 1 | 2009 | 35 | 0.020 |
Why?
| Thyroxine | 1 | 2008 | 59 | 0.020 |
Why?
| Outpatient Clinics, Hospital | 1 | 2009 | 79 | 0.020 |
Why?
| Child | 2 | 2022 | 18489 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 724 | 0.020 |
Why?
| Curriculum | 1 | 2014 | 852 | 0.020 |
Why?
| Osteocytes | 1 | 2008 | 22 | 0.020 |
Why?
| Breath Tests | 1 | 2007 | 83 | 0.020 |
Why?
| Clone Cells | 1 | 2008 | 248 | 0.020 |
Why?
| Laparoscopy | 1 | 2011 | 400 | 0.020 |
Why?
| Databases as Topic | 1 | 2007 | 64 | 0.020 |
Why?
| Job Satisfaction | 1 | 2009 | 170 | 0.020 |
Why?
| Cell Movement | 1 | 2011 | 867 | 0.020 |
Why?
| Social Environment | 1 | 2009 | 286 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 446 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2012 | 1216 | 0.020 |
Why?
| Pyridines | 1 | 2010 | 425 | 0.020 |
Why?
| Glycoproteins | 1 | 2008 | 309 | 0.020 |
Why?
| Models, Biological | 1 | 2014 | 1646 | 0.020 |
Why?
| Trauma Centers | 1 | 2009 | 329 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2007 | 515 | 0.020 |
Why?
| Adipocytes | 1 | 2008 | 188 | 0.020 |
Why?
| Antigens, CD | 1 | 2008 | 442 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2007 | 287 | 0.020 |
Why?
| Cell Lineage | 1 | 2008 | 310 | 0.020 |
Why?
| Telomerase | 1 | 2008 | 206 | 0.020 |
Why?
| Chondrocytes | 1 | 2008 | 199 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2008 | 1357 | 0.010 |
Why?
| Health Care Costs | 1 | 2007 | 384 | 0.010 |
Why?
| France | 1 | 2003 | 34 | 0.010 |
Why?
| Peptides | 1 | 2008 | 864 | 0.010 |
Why?
| Hypoxia | 1 | 2009 | 937 | 0.010 |
Why?
| Contraindications | 1 | 2003 | 86 | 0.010 |
Why?
| Washington | 1 | 2003 | 134 | 0.010 |
Why?
| Cardiac Output | 1 | 2003 | 143 | 0.010 |
Why?
| Cell Proliferation | 1 | 2008 | 2194 | 0.010 |
Why?
| Analysis of Variance | 1 | 2003 | 1227 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|